Hap Trading, LLC Cardiff Oncology, Inc. Call Options Transaction History

Hap Trading, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	BUY	$1.17 - $2.61 $12,051 - $26,883	10,300 New	10,300 $1,000
Q2 2021 Aug 11, 2021	SELL	$6.65 - $10.04 $68,495 - $103,411	-10,300 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$9.1 - $19.57 $98,280 - $211,356	-10,800 Reduced 51.18%	10,300 $3,000
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $275,258 - $565,859	-22,900 Reduced 52.05%	21,100 $181,000
Q3 2020 Nov 13, 2020	BUY	$4.25 - $14.19 $187,000 - $624,360	44,000 New	44,000 $188,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $185M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.